Hester Biosciences Limited (BOM:524669)
India · Delayed Price · Currency is INR 1,559.95
-18.80 (-1.19%)
At close: Feb 13, 2026
Hester Biosciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 3,144 | 3,111 | 3,045 | 2,661 | 2,350 | 2,143 |
Other Revenue | 13.72 | 13.72 | 66.48 | 121.14 | 116.41 | 33.64 |
| 3,158 | 3,125 | 3,112 | 2,782 | 2,466 | 2,177 | |
Revenue Growth (YoY) | -1.15% | 0.41% | 11.86% | 12.80% | 13.30% | 15.94% |
Cost of Revenue | 877.65 | 928.37 | 997.28 | 824.81 | 678.19 | 527.1 |
Gross Profit | 2,280 | 2,196 | 2,115 | 1,957 | 1,788 | 1,650 |
Selling, General & Admin | 709.17 | 728.49 | 752.69 | 675.39 | 516.02 | 440.33 |
Other Operating Expenses | 842.26 | 843.64 | 758.94 | 654.62 | 536.16 | 478.27 |
Operating Expenses | 1,723 | 1,740 | 1,683 | 1,537 | 1,238 | 1,059 |
Operating Income | 557.35 | 456.22 | 431.29 | 420.28 | 550.43 | 591.22 |
Interest Expense | -70.96 | -83.4 | -91.19 | -51.49 | -25.76 | -60.62 |
Interest & Investment Income | 20.37 | 20.37 | 19.07 | 21.73 | 19.03 | 12.94 |
Earnings From Equity Investments | 58.26 | 41 | 46.09 | 44.09 | 4.23 | - |
Currency Exchange Gain (Loss) | -33.62 | -33.62 | -94.68 | -29.92 | -4.59 | -4.03 |
Other Non Operating Income (Expenses) | 13.52 | -4.86 | -3.1 | -3.31 | -9.57 | -5.42 |
EBT Excluding Unusual Items | 544.92 | 395.71 | 307.48 | 401.38 | 533.77 | 534.09 |
Gain (Loss) on Sale of Assets | - | - | 0.28 | 0.16 | 1.25 | 0.15 |
Other Unusual Items | - | - | 11.77 | - | - | -33.21 |
Pretax Income | 544.92 | 395.71 | 319.53 | 401.54 | 535.02 | 501.03 |
Income Tax Expense | 120.14 | 107.45 | 107.87 | 121.19 | 140.18 | 154.05 |
Earnings From Continuing Operations | 424.78 | 288.26 | 211.66 | 280.35 | 394.84 | 346.98 |
Minority Interest in Earnings | -15.31 | -13.38 | -22.77 | -14.08 | -1.64 | -2.68 |
Net Income | 409.47 | 274.88 | 188.89 | 266.27 | 393.2 | 344.3 |
Net Income to Common | 409.47 | 274.88 | 188.89 | 266.27 | 393.2 | 344.3 |
Net Income Growth | 31.46% | 45.52% | -29.06% | -32.28% | 14.20% | 18.03% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 |
Shares Change (YoY) | -0.58% | - | - | - | - | - |
EPS (Basic) | 47.83 | 32.31 | 22.20 | 31.30 | 46.22 | 40.47 |
EPS (Diluted) | 47.83 | 32.31 | 22.20 | 31.30 | 46.22 | 40.47 |
EPS Growth | 32.23% | 45.52% | -29.06% | -32.28% | 14.20% | 18.03% |
Free Cash Flow | - | 439.2 | 237.86 | -541.66 | -869.98 | 173.11 |
Free Cash Flow Per Share | - | 51.63 | 27.96 | -63.67 | -102.27 | 20.35 |
Dividend Per Share | - | 7.000 | 6.000 | 8.000 | 10.000 | 10.000 |
Dividend Growth | - | 16.67% | -25.00% | -20.00% | - | 51.52% |
Gross Margin | 72.21% | 70.29% | 67.95% | 70.35% | 72.50% | 75.79% |
Operating Margin | 17.65% | 14.60% | 13.86% | 15.11% | 22.32% | 27.16% |
Profit Margin | 12.97% | 8.80% | 6.07% | 9.57% | 15.94% | 15.82% |
Free Cash Flow Margin | - | 14.06% | 7.64% | -19.47% | -35.27% | 7.95% |
EBITDA | 718.13 | 620.39 | 599.98 | 624.22 | 712.92 | 720.33 |
EBITDA Margin | 22.74% | 19.85% | 19.28% | 22.44% | 28.90% | 33.09% |
D&A For EBITDA | 160.78 | 164.17 | 168.69 | 203.94 | 162.49 | 129.11 |
EBIT | 557.35 | 456.22 | 431.29 | 420.28 | 550.43 | 591.22 |
EBIT Margin | 17.65% | 14.60% | 13.86% | 15.11% | 22.32% | 27.16% |
Effective Tax Rate | 22.05% | 27.15% | 33.76% | 30.18% | 26.20% | 30.75% |
Revenue as Reported | 3,202 | 3,150 | 3,152 | 2,812 | 2,487 | 2,190 |
Advertising Expenses | - | 77.73 | 88.06 | 99.74 | 49.63 | 37.96 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.